How is Our Research Funded?
As a 501(c)(3) non-profit corporation, funding for NFFRE studies comes from industry, government, and non-profit organizations.
Industry sponsors invite collaborating organizations to assist with conducting their research protocols. Some of our prominent industry sponsors include AstraZeneca, Boston Scientific, Cirius Therapeutics, Kowa Research Institute, Novartis, Phillips Respironics, and Sanofi.
Government and non-profit organizations provide grants for research in specific scientific areas of interest, which scientists compete for. NFFRE has received grants from government agencies such the Department of Defense, the Department of Veterans Affairs, and the National Institutes of Health (NIH) and from private foundations such as the Craig H. Neilsen Foundation.
CHRONICLE (A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States)
Principal Investigator: Peruvemba S. Sriram, MD
The CHRONICLE Study will provide a contemporary description of the epidemiology and medical management of US adults with severe asthma who have not achieved control with high-dose ICS therapy and additional controllers. Additionally, the study will describe the use of and outcomes associated with recently approved monoclonal antibody therapies for severe asthma. The primary objective of the CHRONICLE Study is to describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
ASLeap (A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg)
Principal Investigator: Michael Bubb, MD
This randomized, double-blind, parallel-group, multicenter study of secukinumab is designed to estimate the difference in clinical response between 300 mg and 150 mg of secukinumab at Week 52, which follows randomization to dose escalation at Week 16 for patients with Ankylosing Spondylitis who inadequately respond to open-label secukinumab 150 mg. This study will also investigate the association between treatment andsleep disturbances, as well as daytime activity patterns.